BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Easton Pharmaceuticals (OP: EAPH) Announces Completion of Name Change From LAM Industries


3/22/2010 10:40:04 AM

TORONTO, ONTARIO--(Marketwire - March 22, 2010) - Easton Pharmaceuticals Inc. (PINK SHEETS: EAPH) (the "Company") announces it has completed its name change from LAM Industries to Easton Pharmaceuticals Inc, as previously released. Concurrent with its name change, the company's stock trading symbol and cusip # have also changed. Its new stock symbol is EAPH. The company's new cusip number is 277774 105.

John Easton, Chairman of Easton Pharmaceuticals stated, "We are excited to continue to execute on our corporate strategy starting with the change of the company's name". Mr. Easton further commented, "We are energized and focused on our corporate objectives of product commercialization, launch and expansion of our business throughout 2010 and beyond".

About Easton Pharmaceuticals

Easton Pharmaceuticals maintains a portfolio of commercial and under development products utilizing the "VDM" technology. Easton Pharmaceuticals current strategic focus is the final commercialization and launch of its flagship product, Viorra, an over-the-counter aid for the treatment of FSAD (Female Sexual Arousal Disorder). Viorra is a topical, daily use product containing Generally Regarded as Safe substances as classified by the FDA. Easton Pharmaceuticals has created a comprehensive business and marketing strategy for Viorra, which the Company believes requires no further development and is currently ready for marketing and sale in a number of markets.

For more information please visit http://www.eastonpharmaceuticals.com


Contacts:
Easton Pharmaceuticals Inc.
+1 (416) 619-0291
+1 (347) 284-0192
+1 (888) 877-3723 (FAX)
ir@eastonpharma.com
www.eastonpharmaceuticals.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES